Form 4: United Therapeutics CFO James Edgemond Executes Stock Options and Sells Shares Under 10b5-1 Plan

James Edgemond, CFO and Treasurer of United Therapeutics, exercised stock options and sold shares of common stock on September 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On September 16, 2024, James Edgemond, the CFO and Treasurer of United Therapeutics Corp, executed stock options and sold shares of the company's common stock.
• These transactions were carried out under a pre-existing Rule 10b5-1 trading plan established on May 17, 2024.
• Edgemond exercised options to acquire a total of 8,334 shares at prices of $120.26 and $117.76.
• Simultaneously, he sold a total of 4,809 shares at a price of $339.12 per share.
• Some of the option exercises were 'sell-to-cover' transactions, where a portion of the acquired shares were immediately sold to cover the exercise cost.
• Following these transactions, Edgemond directly owns 4,264 shares of common stock.
• He also holds derivative securities in the form of stock options for 141,250 and 142,100 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity under a pre-arranged plan. It doesn't inherently reflect a positive or negative view of the company's prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It's common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information. The filing itself doesn't necessarily indicate a positive or negative outlook for the company.

Key Dates